Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Interventional × lifileucel × Clear all

Phase

Status

Recruiting 6 Active not recruiting 2 Withdrawn 1 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 1479 Cisplatin 1399 Paclitaxel 1308 Radiotherapy 1251 Carboplatin 1238 Gemcitabine 1208 Docetaxel 1106 Bevacizumab 1022 Fluorouracil 888 Doxorubicin 779 Dexamethasone 740 Rituximab 717 Capecitabine 715 Oxaliplatin 696 Etoposide 669 pembrolizumab 657 Irinotecan 629 Filgrastim 620 Cytarabine 582 Leucovorin 573 Nivolumab 546 Vincristine 505 Prednisone 470 Cetuximab 460 Bortezomib 456 Erlotinib Hydrochloride 455 Trastuzumab 447 Methotrexate 434 Lenalidomide 426 Pemetrexed 417

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02360579 2026-03-25

LN-144

Iovance Biotherapeutics, Inc.

Phase 2 Completed

220 enrolled 16 charts 1 FDA

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡